CJC-1295
Long-acting GHRH analog
- Class
- GHRH analog
- Half-life
- Variable
- Route
- Subcutaneous (SubQ)
- Cadence
- Multiple per week
- Evidence
- Mixed / early human
Overview
CJC-1295 is a synthetic version of the hormone your hypothalamus uses to tell your pituitary to make growth hormone (GHRH). It comes in two flavours and they are NOT the same drug — pay attention to which one you have.
The "DAC" version sticks to your blood albumin and lasts about 8 days, producing a long sustained elevation of GH and IGF-1 — a pattern your body never makes on its own. The "no-DAC" version (sometimes labelled Modified GRF 1-29) has a half-life of about 30 minutes and gives you brief GH pulses closer to natural physiology. The no-DAC is what most people actually use, almost always stacked with ipamorelin for a bigger combined pulse.
The DAC variant reached Phase 2 trials for HIV lipodystrophy and was discontinued in 2006. The no-DAC variant is the most common form on the research market today.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved anywhere. The DAC version's clinical trials were stopped; the no-DAC version was never developed past early research.
- DAC version's sustained GH/IGF-1 elevation is the bigger safety unknown — insulin resistance over months is the most likely issue.
- Carpal tunnel, joint aches, and fluid retention scale with dose. These are dose-dependent and reversible if you back off.
+ 2 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching CJC-1295.
- IGF-1 (the main signal that the drug is doing anything)
- Fasting glucose / HbA1c — GH suppresses insulin sensitivity
- Body composition (DEXA quarterly is the gold standard; tape and photos work too)
- Blood pressure — some reports of orthostatic drops at higher DAC doses
- Carpal tunnel / finger tingling at higher doses
Frequently asked questions
What is CJC-1295?
Long-acting GHRH analog. CJC-1295 is a synthetic version of the hormone your hypothalamus uses to tell your pituitary to make growth hormone (GHRH). It comes in two flavours and they are NOT the same drug — pay attention to which one you have.
How is CJC-1295 administered?
Subcutaneous (SubQ), typically multiple per week.
What is the half-life of CJC-1295?
Variable — DAC version: 6-8 days (Teichman 2006) · no-DAC version: ~30 min — wildly different drugs.
Is CJC-1295 approved for human use?
CJC-1295 is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for CJC-1295?
Evidence tier: Mixed / early human. Teichman 2006 (the only published PK study in healthy adults) established the DAC version's 6-8 day half-life (reported as 5.8-8.1 days) and showed sustained GH/IGF-1 elevation in the supraphysiological range. That's the dataset everyone cites.
What is commonly monitored when researching CJC-1295?
Commonly tracked markers + signals: IGF-1 (the main signal that the drug is doing anything), Fasting glucose / HbA1c — GH suppresses insulin sensitivity, Body composition (DEXA quarterly is the gold standard; tape and photos work too), Blood pressure — some reports of orthostatic drops at higher DAC doses, Carpal tunnel / finger tingling at higher doses.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.